REFERENCES
- G. E. Amidon, G. E. Peck, L. H. Block, R. C. Moreton, A. Katdare, R. Lafaver, and C. Sheehan. (2007). Proposed new USP general information chapter, excipient performance <1059>. Pharmacopoeial Forum 33:1311–1323.
- P. Begat, D. A. V. Morton, J. N. Staniforth, and R. Price. (2004). The cohesive-adhesive balances in dry powder inhaler formulations I: Direct quantification by atomic force microscopy. Pharm. Res. 21:1591–1597.
- http://www.fda.gov/cder/guidance/2180dft.htm CDER. (1998). Guidance for industry: Metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products (draft). Rockville, MD: United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,.
- A. H. Chow, H. H. Tong, P. Chattopadhyay, and B. Y. Shekunov. (2007). Particle engineering for pulmonary drug delivery. Pharm. Res. 24:411–437.
- www.emea.europa.eu/pdfs/human/qwp/4931305en.pdf. London, 12 June 2006 EMEA. (2006). Committee for Medicinal Products for Human Use. Guidance on the pharmaceutical quality of inhalation and nasal products..
- http://online.pheur.org European Pharmacopoeia. (2008). (6th ed., Suppl. 2). Strasbourg, France: Council of Europe,.
- A. J. Hickey, H. M. Mansour, M. J. Telko, Z. Xu, H. D. Smyth, T. Mulder, R. McLean, J. Langridge, and D. Papadopoulos. (2007). Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J. Pharm. Sci. 96:1282–1301.
- http://www.ich.org/LOB/media/MEDIA1707.pdf ICH. (2006). International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Quality 8 (International conference on harmonization, 15, chemin Louis-Dunant, P.O. Box 195, 1211 Geneva 20, Switzerland, May 2006),.
- S. K. Kaerger, R. Price, P. M. Young, S. Edge, and M. J. Tobyn. (2006). Carriers for DPIs: Formulation and regulatory challenges. Pharm. Tech. Europe 18:25–30.
- T. Kieckbusch, F. Eskandar, M. Lejeune, S. Edge, D. Ziegler, and M. Dalvi. Low mass powder dosing system—from laboratory scale to pilot scaleProceedings of Drug Delivery to the Lungs XVIIIEdinburgh, UK, (December 2007), 12–14.
- M. Morisset, D. Moneret-Vautrin, N. Commun, A. Schuller, and G. Kanny. (2006). Allergy to cow milk proteins contaminating lactose, common excipient of dry powder inhalers for asthma. J. Allergy Clin. Immunol. 117 (2, Suppl. 1):S95.
- H. E. Newell, G. Buckton, D. A. Butler, F. Thielmann, and D. R. Williams. (2001). The use of inverse phase gas chromatography to study the change of surface energy of amorphous lactose as a function of relative humidity and the processes of collapse and crystallization. Int. J. Pharm. 217:45–56.
- A. Nowak-Wegrzyn, G. G. Shapiro, K. Beyer, L. Ludmila Bardina, and H. A. Sampson. (2004). Contamination of dry powder inhalers for asthma with milk proteins containing lactose. J. Allergy Clin. Immunol. 113:558–560.
- O. Planinšek, A. Trojak, and S. Srcic. (2001). The dispersive component of the surface free energy of powders assessed using inverse gas chromatography and contact angle measurements. Int. J. Pharm. 221:211–217.
- R. Price, P. M. Young, S. Edge, and J. N. Staniforth. (2002). The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations. Int. J. Pharm. 246:47–59.
- Handbook of pharmaceutical excipients5thR. C. Rowe, P. J. Sheskey, and S. C. Owen. Pharmaceutical Press, London, (2005).
- G. Rowley, and L. A. Mackin. (2003). The effect of moisture sorption on electrostatic charging of selected pharmaceutical excipient powders. Powder Technol. 135–136:50–58.
- V. V. Sethuraman, A. J. Hickey. (2002). Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug. AAPS PharmSciTech., 3(4), E28, Retrieved September 8, 2008, from http://www.aapspharmscitech.org.
- V. Swaminathan, J. Cobb, and I. Saracovan. (2006). Measurement of the surface energy of lubricated pharmaceutical powders by inverse gas chromatography. Int. J. Pharm. 312:158–165.
- M. J. Telko, and A. J. Hickey. (2005). Dry powder inhaler formulation. Respir. Care 50:1209–1227.
- M. J. Telko, and A. J. Hickey. (2007). Critical assessment of inverse gas chromatography as means of assessing surface free energy and acid–base interaction of pharmaceutical powders. J. Pharm. Sci. 96:2647–2654.
- M. D. Ticehurst, P. York, R. C. Rowe, and S. K. Dwivedi. (1996). Characterisation of the surface properties of alpha-lactose monohydrate with inverse gas chromatography, used to detect batch variation. Int. J. Pharm. 141:93–99.
- www.uspnf.com United States Pharmacopoeia. (31st Rev. ed.), The National Formulary (26th Rev. ed.) (Suppl. 1) (2008). Rockville, MD: The United States Pharmacopoeial Convention, Inc,.